

IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

Claims 1-21 (canceled)

22. (previously presented) An immunogenic composition, wherein the composition is created from preparations obtained by:

- (a) incubation of first cells expressing target receptor(s) of an infectious pathogenic agent, causing infections in a mammal by bonding and then fusion with target cells, with second cells expressing at least regions of the infectious pathogenic agent recognizing the said target receptor(s) under conditions enabling interaction of said first cells and said second cells so as to form a complex, this incubation step being done with different intervals in order to produce complexes corresponding to different fusion stages, and
- (b) putting the complexes formed into contact with a binding agent for different intervals, in order to bind complexes with different exposures and conformations of epitopes against which antibodies are to be formed, the said first cells and said second cells being tolerated by mammals.

23. (previously presented) The composition of claim 22, wherein said first cells are autologous mammalian cells.

24. (previously presented) The composition of claim 22, wherein said first cells are transformed with vectors comprising genes expressing the target receptor(s).

Claim 25 (canceled)

26. (previously presented) The composition of claim 22, wherein said second cells are transformed with vectors carrying at least one bonding region to at least one receptor.

27. (previously presented) The composition of claim 22, wherein said second cells are transformed with viral vectors carrying at least one bonding region to a target receptor.

28. (previously presented) The composition of claim 22, wherein said second cells are infected cells that produce infectious pathogenic agents or are composed of infectious pathogenic agents.

29. (previously presented) The composition of claim 22, wherein said infectious pathogenic agent is a virus.

30. (previously presented) The composition of claim 29, wherein said pathogenic agent is HIV.

31. (previously presented) The composition of claim 22, wherein said preparations are obtained by incubation of first cells expressing the CD4 receptor and/or HIV co-receptors with second cells expressing at least the preserved regions in gp120 or gp160 envelope proteins.

32. (previously presented) The composition of claim 31, wherein said first cells are autologous mammalian cells stimulated so as to express the CD4 receptor and/or HIV co-receptors, in a sufficient quantity for the required interaction.

33. (previously presented) The composition of claim 31, wherein said first cells are transformed with viral vectors comprising genes expressing CD4 and/or HIV co-receptors.

Claims 34 (canceled)

35. (previously presented) The composition of claim 31, wherein said second cells are transformed with viral vectors comprising at least regions of HIV-1 gp120 or HIV-1 gp160 envelope proteins.

36. (previously presented) The composition of claim 31, wherein said second cells are infected cells producing HIV or are composed of the HIV virus itself.

37. (previously presented) The composition of claim 31, wherein said second cells express HIV-1 gp120 or HIV-1 gp160 envelope proteins in natural or recombining form.

38. (previously presented) The composition of claim 31, wherein one of the co-receptors of HIV is replaced by a monoclonal antibody directed to a region of gp120 which binds to HIV-1 co-receptors.

Claim 39 (canceled)

40. (previously presented) The composition of claim 22, wherein said preparations are fixed with aldidrithiol-2 after incubation.

41. (previously presented) An isolated serum or antibody formed against the composition of claim 22.

42. (previously presented) The composition of claim 22, further comprising an inert vehicle acceptable for administration to a mammal, and optionally with an additive.

43. (previously presented) The composition of claim 24, wherein said vectors are viral vectors.

44. (previously presented) The composition of claim 28, wherein said infectious pathogenic agents are selected from the group consisting of a retrovirus, a bacteria, a mycobacteria, and a parasite.

45. (withdrawn) The composition of claim 28, wherein said infectious pathogenic agents are selected from the group consisting of a *Plasmodium sp.*, a *Leishmania sp.*, *Trypanosoma cruzi* and *Trypanosoma brucei*.

46. (withdrawn) The composition of claim 23, wherein said first cells are healthy human cells taken from a patient to be vaccinated.

47. (previously presented) The composition of claim 33, wherein the viral vectors are baculoviruses or Semliki forest viruses.

48. (withdrawn) The composition of claim 31, wherein said first cells are yeast expressing CD4 and/or HIV co-receptors at their surface.

49. (withdrawn) The composition of claim 48, wherein said yeast are *Saccharomyces cerevisiae*.

50. (previously presented) An immunogenic composition for forming serum or antibody recognizing an infectious pathogenic agent, wherein the composition is created from preparations obtained by:

- (a) incubation of first cells expressing target receptor(s) of an infectious pathogenic agent, causing infections in a mammal by bonding and then fusion with target cells, with second cells expressing at least regions of the infectious pathogenic agent recognizing the said target receptor(s) under conditions enabling interaction of said first cells and said second cells so as to form a complex, this incubation step being done with different intervals in order to produce complexes corresponding to different fusion stages, and

- (b) putting the complexes formed into contact with a binding agent for different intervals, in order to bind complexes with different exposures and conformations of epitopes against which antibodies are to be formed, the said first cells and said second cells being tolerated by mammals.

51. (previously presented) An isolated serum or antibody for recognition of an infectious pathogenic agent, wherein said serum or antibody is formed against the composition of claim 50.